Joshua Bauml, MD

Emerging data indicate that patients with metastasis to a limited number of sites may have improved outcomes with the use of locally ablative therapy. The availability of minimally invasive LAT has led to the widespread adoption of this practice for patients with oligometastatic disease. There are currently no clear predictors of improved survival after LAT across tumor subtypes. New data suggest the use of molecular biomarkers and combination therapies improve patient outcomes.

Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.